PT - JOURNAL ARTICLE AU - Xue Ling Zhang AU - Jia Huan Sun AU - Yue Wu AU - Min Xie AU - Cong Cong Li AU - Dong Lv AU - Wei Yu AU - Pei Lin Cui TI - Therapeutic effects of PTCD and ERCP in patients with obstructive severe acute biliary pancreatitis AID - 10.1101/2022.04.29.22274457 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.29.22274457 4099 - http://medrxiv.org/content/early/2022/06/23/2022.04.29.22274457.short 4100 - http://medrxiv.org/content/early/2022/06/23/2022.04.29.22274457.full AB - Objective We evaluated the therapeutic effects of PTCD and ERCP in patients with obstructive severe acute biliary pancreatitis (SABP).Methods A total of 62 patients with obstructive SABP were enrolled in this study from July 2013 to July 2019 and divided into three groups: PTCD group (n=22), ERCP group (n=24) and conservative group (n=16). Based on treatment time, PTCD and ERCP groups were further separated into early (⩽ 72 h) and delayed (>72 h) groups. Laboratory indices, hospitalization days, recovery of liver functions and remission of abdominal pain as well as complications were evaluated to establish the efficacy and suitable time.Results The average hospitalization days, time for abdominal pain relief and laboratory indices (leukocyte, blood amylase, ALT and TBiL) recovery were shorter (p<0.05) in PTCD and ERCP groups. The average hospitalization days for the ERCP group (16.71±3.99) were shorter, compared to the PTCD group (19.64±4.27) (p<0.05). Complications were few in ERCP (33.33%) and PTCD (27.27%) groups. The average length of stay (13.88±3.27), recovery time of leukocyte (6.31±0.92) and TBiL (9.13±1.98) in the early ERCP group were shorter than in both delayed ERCP and early PTCD groups (p<0.05). The average length of stay (18.63±4.06) and ALT recovery time (12.25±2.59) in delayed ERCP group were shorter than in delayed PTCD group (p<0.05).Conclusions Both ERCP and PTCD are effective for relieving biliary obstruction during SABP, and early ERCP or PTCD within 72 h for obstructive SABP are more beneficial.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (No. XXT14).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies that use datasets obtained via personal communication or databases that require application, screening or registration for access Ethics committee of Beijing Tiantan Hospital, Capital Medical University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsPTCDPercutaneous transhepatic cholangial drainageERCPEndoscopic retrograde cholangiopancreatographyABPAcute biliary pancreatitisSABPSevere acute biliary pancreatitisMABPMild acute biliary pancreatitisSIRSSystemic inflammation response syndromeMODSMultiple organ dysfunction syndromePOFPersistent organ failure